



Glioblastomas

Guest Editor:

Dr. Gaetano Finocchiaro

Foundation IRCCS Neurological
Institute "C. Besta", Milan, Italy

Deadline for manuscript
submissions:

closed (26 June 2021)

Message from the Guest Editor

Dear Colleagues,

Glioblastoma (GBM: the “M” keeps a signature of the old definition, “multiforme”) remains the most aggressive of gliomas and all primary brain tumors. Primary GBMs are those that present themselves as such since disease onset, without a previous history of lower-grade gliomas. In this series of papers hosted by “Cancers” we would like not only to point out what the state of the art is at present but also to add novel data and intriguing findings deriving from the considerable research flow on GBM that is growing in recent years.

The other area of research is related to the characterization of the immunological texture of GBM. The recent, negative results of phase III immunotherapy studies with checkpoint inhibitors and vaccines based on specific mutations like EGFRvIII, are telling us that without an in-depth understanding of immunosuppressive strategies of GBM it will be difficult to design a second wave of immunotherapy therapeutic “attacks” with increased chances of success.

Dr. Gaetano Finocchiaro

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)